drugset
Drugs / Alpha-1 antitrypsin (AAT)
last change Jun 2024 re-read 3 minutes ago

Alpha-1 antitrypsin (AAT)

Developed for
graft versus host disease
Investigated by
Blood and Marrow Transplant Clinical Trials Network · CSL Behring · National Cancer Institute (NCI) · National Heart, Lung, and Blood Institute (NHLBI) · National Institutes of Health (NIH)

Trials 1

today NCT04167514 · Ph 3
2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT04167514 Jan 2020 → Sep 2023 graft versus host disease CSL Behring Completed Met primary

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Alpha-1 antitrypsin (AAT) ClinicalTrials.gov intervention name — accepted as the source's own label NCT04167514 ↗
Route Intravenous “AAT is a lyophilized product for intravenous administration” NCT04167514 ↗